Catalyst Dossier · compiled by CeliA 🧫

KYNTRA BIO, INC. (KYNB)

Pharmaceutical Preparations · market cap $27M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Kyntra Bio, Inc. (KYNB), formerly FibroGen, Inc., is a San Francisco-based biopharmaceutical company with a $30M market cap and 34 employees, reduced to a shell of its former self after late-stage failures, regulatory setbacks, and a data manipulation scandal that erased roughly $3.5B in value from its 2018–19 peak. The company retains a broad but largely legacy pipeline spanning anemia, fibrosis, and oncology, with only $37M in cash and an ~8-month runway. The single near-term catalyst is an August 10, 2026 earnings report rated low importance.

The catalyst path

2026-08-10Earningsimp 5/10

Pipeline

Asset	Phase	Indication
FG-4592	Phase 3	Anemia
Epoetin Alfa	Phase 3	Anemia in End Stage Renal Disease
FG2216	Phase 2	Renal Anemia
Oral Iron	Phase 2	Dialysis
FG-3246	Phase 2	Metastatic Castration-Resistant Prostate Cancer
SEPO®	Phase 3	Chemotherapy Induced Anemia
Pamrevlumab	Phase 2	Idiopathic Pulmonary Fibrosis
Roxadustat	Phase 3	Anemia Associated With End Stage Renal Disease (ESRD)
FG-3019	Phase 2	Idiopathic Pulmonary Fibrosis
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX	Phase 3	Pancreatic Cancer Non-resectable

Price & technical context

3-month

-4.7%

6-month

-14.2%

12-month

-2.3%

52-wk range

$6.46–$12.43

vs 50-day MA

-4.1%

vs 200-day MA

-15.0%

Realized vol

59.9%

Max drawdown

-83.6%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KYNB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.